View ValuationSai Life Sciences 将来の成長Future 基準チェック /36Sai Life Sciences利益と収益がそれぞれ年間18.8%と16.8%増加すると予測されています。EPS は年間 増加すると予想されています。自己資本利益率は 3 年後に16.3% 18.6%なると予測されています。主要情報18.8%収益成長率18.55%EPS成長率Life Sciences 収益成長23.9%収益成長率16.8%将来の株主資本利益率16.31%アナリストカバレッジGood最終更新日22 Jul 2026今後の成長に関する最新情報Price Target Changed • May 20Price target increased by 8.0% to ₹1,275Up from ₹1,181, the current price target is an average from 6 analysts. New target price is 12% above last closing price of ₹1,141. Stock is up 54% over the past year. The company is forecast to post earnings per share of ₹19.35 for next year compared to ₹16.63 last year.すべての更新を表示Recent updatesお知らせ • Jul 01Sai Life Sciences Limited to Report Q1, 2027 Results on Aug 06, 2026Sai Life Sciences Limited announced that they will report Q1, 2027 results on Aug 06, 2026Price Target Changed • May 20Price target increased by 8.0% to ₹1,275Up from ₹1,181, the current price target is an average from 6 analysts. New target price is 12% above last closing price of ₹1,141. Stock is up 54% over the past year. The company is forecast to post earnings per share of ₹19.35 for next year compared to ₹16.63 last year.Reported Earnings • May 16Full year 2026 earnings: EPS and revenues miss analyst expectationsFull year 2026 results: EPS: ₹16.63 (up from ₹8.83 in FY 2025). Revenue: ₹22.4b (up 32% from FY 2025). Net income: ₹3.49b (up 105% from FY 2025). Profit margin: 16% (up from 10.0% in FY 2025). The increase in margin was driven by higher revenue. Revenue missed analyst estimates by 1.7%. Earnings per share (EPS) also missed analyst estimates by 3.0%. Revenue is forecast to grow 16% p.a. on average during the next 3 years, compared to a 17% growth forecast for the Life Sciences industry in India.お知らせ • Apr 21Sai Life Sciences Limited to Report Q4, 2026 Results on May 14, 2026Sai Life Sciences Limited announced that they will report Q4, 2026 results at 4:00 PM, Indian Standard Time on May 14, 2026Buy Or Sell Opportunity • Feb 12Now 20% undervaluedOver the last 90 days, the stock has risen 6.7% to ₹930. The fair value is estimated to be ₹1,167, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 21% over the last 3 years. Earnings per share has grown by 69%. Revenue is forecast to grow by 38% in 2 years. Earnings are forecast to grow by 51% in the next 2 years.Reported Earnings • Feb 06Third quarter 2026 earnings: EPS and revenues exceed analyst expectationsThird quarter 2026 results: EPS: ₹4.77 (up from ₹2.89 in 3Q 2025). Revenue: ₹5.65b (up 28% from 3Q 2025). Net income: ₹1.00b (up 86% from 3Q 2025). Profit margin: 18% (up from 12% in 3Q 2025). The increase in margin was driven by higher revenue. Revenue exceeded analyst estimates by 1.4%. Earnings per share (EPS) also surpassed analyst estimates by 21%. Revenue is forecast to grow 15% p.a. on average during the next 3 years, compared to a 17% growth forecast for the Life Sciences industry in India.お知らせ • Jan 22Sai Life Sciences Limited to Report Q3, 2026 Results on Feb 05, 2026Sai Life Sciences Limited announced that they will report Q3, 2026 results on Feb 05, 2026Reported Earnings • Nov 07Second quarter 2026 earnings: EPS and revenues exceed analyst expectationsSecond quarter 2026 results: EPS: ₹4.01 (up from ₹2.22 in 2Q 2025). Revenue: ₹5.53b (up 36% from 2Q 2025). Net income: ₹838.4m (up 102% from 2Q 2025). Profit margin: 15% (up from 10% in 2Q 2025). The increase in margin was driven by higher revenue. Revenue exceeded analyst estimates by 8.2%. Earnings per share (EPS) also surpassed analyst estimates by 40%. Revenue is forecast to grow 15% p.a. on average during the next 3 years, compared to a 17% growth forecast for the Life Sciences industry in India.お知らせ • Oct 24Sai Life Sciences Limited to Report Q2, 2026 Results on Nov 06, 2025Sai Life Sciences Limited announced that they will report Q2, 2026 results at 4:00 PM, Indian Standard Time on Nov 06, 2025お知らせ • Aug 08Sai Life Sciences Limited, Annual General Meeting, Sep 11, 2025Sai Life Sciences Limited, Annual General Meeting, Sep 11, 2025, at 10:30 Indian Standard Time.Reported Earnings • Aug 08First quarter 2026 earnings: EPS and revenues exceed analyst expectationsFirst quarter 2026 results: EPS: ₹2.90 (up from ₹0.75 in 1Q 2025). Revenue: ₹5.06b (up 50% from 1Q 2025). Net income: ₹604.6m (up 332% from 1Q 2025). Profit margin: 12% (up from 4.1% in 1Q 2025). The increase in margin was driven by higher revenue. Revenue exceeded analyst estimates by 38%. Earnings per share (EPS) also surpassed analyst estimates. Revenue is forecast to grow 14% p.a. on average during the next 3 years, compared to a 16% growth forecast for the Life Sciences industry in India.お知らせ • Jul 21Sai Life Sciences Limited to Report Q1, 2026 Results on Aug 07, 2025Sai Life Sciences Limited announced that they will report Q1, 2026 results on Aug 07, 2025お知らせ • Jun 20TPG Reportedly to Sell 6% Stake in Sai Life Sciences at Estimated Price of $102 Million in Block DealTPG Inc. (NasdaqGS:TPG) is likely to sell 12.5 million shares representing 6% stake Sai Life Sciences Limited (NSEI:SAILIFE) at an estimated deal size of $102 million, according to a report. The base price of the deal is likely at INR 710 per share which is a discount of 2.5% over the current market price. There will be a 60-day lock-in period for the seller, a CNBC-TV18 report said, citing sources. TPG held over 51.5 million equity shares in the company as on March 31, 2025 through TPG Asia VII SF PTE Ltd, which accounts for a 24.73% stake in this smallcap company. The market capitalisation of the company is at INR 152,300 million.Reported Earnings • May 14Full year 2025 earnings released: EPS: ₹8.83 (vs ₹4.57 in FY 2024)Full year 2025 results: EPS: ₹8.83 (up from ₹4.57 in FY 2024). Revenue: ₹17.3b (up 18% from FY 2024). Net income: ₹1.70b (up 106% from FY 2024). Profit margin: 9.8% (up from 5.7% in FY 2024). The increase in margin was driven by higher revenue. Revenue is forecast to grow 15% p.a. on average during the next 3 years, compared to a 15% growth forecast for the Life Sciences industry in India.Board Change • May 08Less than half of directors are independentFollowing the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 3 non-independent directors. Independent Director Ramesh Iyer was the last independent director to join the board, commencing their role in 2024. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.お知らせ • Apr 23Sai Life Sciences Limited Announces Change of Designation of Sauri Gudlavalleti to Head of Special Projects from Chief Operating Officer, Effective April 23, 2025Sai Life Sciences Limited announced that Mr. Sauri Gudlavalleti, who held the position of Chief Operating Officer, will move into the new role of Head of Special Projects with effect from the close of business on 23 April, 2025. The change in role of Mr. Sauri Gudlavalleti is pursuant his request received in this regard due to his personal commitments. He Ceased to be a part of senior management with effect from 23rd April, 2025.お知らせ • Mar 25Sai Life Sciences Limited Announces Cessation of Rajagopal Srirama Tatta as Independent DirectorSai Life Sciences Limited announced cessation of Mr. Rajagopal Srirama Tatta as Independent Director of the Company with effect from the closing of Business hours on 25 March 2025, consequent to the end of his term as an Independent Director.Recent Insider Transactions • Feb 27Insider recently sold ₹51m worth of stockOn the 21st of February, Tuneer Ghosh sold around 71k shares on-market at roughly ₹713 per share. This transaction amounted to 12% of their direct individual holding at the time of the trade. In the last 3 months, there was an even bigger sale from another insider worth ₹109m. Insiders have been net sellers, collectively disposing of ₹830m more than they bought in the last 12 months.Reported Earnings • Feb 07Third quarter 2025 earnings releasedThird quarter 2025 results: EPS: ₹2.89. Net income: ₹538.5m (up ₹538.5m from 3Q 2024). Revenue is forecast to grow 19% p.a. on average during the next 3 years, compared to a 16% growth forecast for the Life Sciences industry in India.お知らせ • Jan 25Sai Life Sciences Limited to Report Q3, 2025 Results on Feb 06, 2025Sai Life Sciences Limited announced that they will report Q3, 2025 results on Feb 06, 2025業績と収益の成長予測BSE:544306 - アナリストの将来予測と過去の財務データ ( )INR Millions日付収益収益フリー・キャッシュフロー営業活動によるキャッシュ平均アナリスト数3/31/202937,3726,1073,2687,24233/31/202832,5005,1938216,10063/31/202726,4554,111-5,9744,75563/31/202621,9253,489-8385,091N/A12/31/202521,6993,329N/AN/AN/A9/30/202520,5322,864-1,9783,055N/A6/30/202519,1132,441N/AN/AN/A3/31/202516,9461,701-5523,140N/A12/31/202415,5431,380N/AN/AN/A9/30/202414,9811,2371532,433N/A6/30/202414,237758N/AN/AN/A3/31/202414,6528288142,631N/A3/31/202312,1711001,0632,194N/A3/31/20228,69662-1,0201,049N/A3/31/20217,599611-2,985-364N/Aもっと見るアナリストによる今後の成長予測収入対貯蓄率: 544306の予測収益成長率 (年間18.8% ) は 貯蓄率 ( 6.9% ) を上回っています。収益対市場: 544306の収益 ( 18.8% ) はIndian市場 ( 16.4% ) よりも速いペースで成長すると予測されています。高成長収益: 544306の収益は増加すると予測されていますが、大幅には増加しません。収益対市場: 544306の収益 ( 16.8% ) Indian市場 ( 11% ) よりも速いペースで成長すると予測されています。高い収益成長: 544306の収益 ( 16.8% ) 20%よりも低い成長が予測されています。一株当たり利益成長率予想将来の株主資本利益率将来のROE: 544306の 自己資本利益率 は、3年後には低くなると予測されています ( 16.3 %)。成長企業の発掘7D1Y7D1Y7D1YPharmaceuticals-biotech 業界の高成長企業。View Past Performance企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/07/23 04:26終値2026/07/23 00:00収益2026/03/31年間収益2026/03/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレークこのレポートを生成するために使用した分析モデルの詳細は、当社のGitHubページでご覧いただけます。また、レポートの活用方法に関するガイドやYouTubeのチュートリアルも用意しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Sai Life Sciences Limited 6 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。9 アナリスト機関Mehul ShethHDFC Securities LimitedRahul JeewaniIIFL ResearchAlok DalalJefferies LLC6 その他のアナリストを表示
Price Target Changed • May 20Price target increased by 8.0% to ₹1,275Up from ₹1,181, the current price target is an average from 6 analysts. New target price is 12% above last closing price of ₹1,141. Stock is up 54% over the past year. The company is forecast to post earnings per share of ₹19.35 for next year compared to ₹16.63 last year.
お知らせ • Jul 01Sai Life Sciences Limited to Report Q1, 2027 Results on Aug 06, 2026Sai Life Sciences Limited announced that they will report Q1, 2027 results on Aug 06, 2026
Price Target Changed • May 20Price target increased by 8.0% to ₹1,275Up from ₹1,181, the current price target is an average from 6 analysts. New target price is 12% above last closing price of ₹1,141. Stock is up 54% over the past year. The company is forecast to post earnings per share of ₹19.35 for next year compared to ₹16.63 last year.
Reported Earnings • May 16Full year 2026 earnings: EPS and revenues miss analyst expectationsFull year 2026 results: EPS: ₹16.63 (up from ₹8.83 in FY 2025). Revenue: ₹22.4b (up 32% from FY 2025). Net income: ₹3.49b (up 105% from FY 2025). Profit margin: 16% (up from 10.0% in FY 2025). The increase in margin was driven by higher revenue. Revenue missed analyst estimates by 1.7%. Earnings per share (EPS) also missed analyst estimates by 3.0%. Revenue is forecast to grow 16% p.a. on average during the next 3 years, compared to a 17% growth forecast for the Life Sciences industry in India.
お知らせ • Apr 21Sai Life Sciences Limited to Report Q4, 2026 Results on May 14, 2026Sai Life Sciences Limited announced that they will report Q4, 2026 results at 4:00 PM, Indian Standard Time on May 14, 2026
Buy Or Sell Opportunity • Feb 12Now 20% undervaluedOver the last 90 days, the stock has risen 6.7% to ₹930. The fair value is estimated to be ₹1,167, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 21% over the last 3 years. Earnings per share has grown by 69%. Revenue is forecast to grow by 38% in 2 years. Earnings are forecast to grow by 51% in the next 2 years.
Reported Earnings • Feb 06Third quarter 2026 earnings: EPS and revenues exceed analyst expectationsThird quarter 2026 results: EPS: ₹4.77 (up from ₹2.89 in 3Q 2025). Revenue: ₹5.65b (up 28% from 3Q 2025). Net income: ₹1.00b (up 86% from 3Q 2025). Profit margin: 18% (up from 12% in 3Q 2025). The increase in margin was driven by higher revenue. Revenue exceeded analyst estimates by 1.4%. Earnings per share (EPS) also surpassed analyst estimates by 21%. Revenue is forecast to grow 15% p.a. on average during the next 3 years, compared to a 17% growth forecast for the Life Sciences industry in India.
お知らせ • Jan 22Sai Life Sciences Limited to Report Q3, 2026 Results on Feb 05, 2026Sai Life Sciences Limited announced that they will report Q3, 2026 results on Feb 05, 2026
Reported Earnings • Nov 07Second quarter 2026 earnings: EPS and revenues exceed analyst expectationsSecond quarter 2026 results: EPS: ₹4.01 (up from ₹2.22 in 2Q 2025). Revenue: ₹5.53b (up 36% from 2Q 2025). Net income: ₹838.4m (up 102% from 2Q 2025). Profit margin: 15% (up from 10% in 2Q 2025). The increase in margin was driven by higher revenue. Revenue exceeded analyst estimates by 8.2%. Earnings per share (EPS) also surpassed analyst estimates by 40%. Revenue is forecast to grow 15% p.a. on average during the next 3 years, compared to a 17% growth forecast for the Life Sciences industry in India.
お知らせ • Oct 24Sai Life Sciences Limited to Report Q2, 2026 Results on Nov 06, 2025Sai Life Sciences Limited announced that they will report Q2, 2026 results at 4:00 PM, Indian Standard Time on Nov 06, 2025
お知らせ • Aug 08Sai Life Sciences Limited, Annual General Meeting, Sep 11, 2025Sai Life Sciences Limited, Annual General Meeting, Sep 11, 2025, at 10:30 Indian Standard Time.
Reported Earnings • Aug 08First quarter 2026 earnings: EPS and revenues exceed analyst expectationsFirst quarter 2026 results: EPS: ₹2.90 (up from ₹0.75 in 1Q 2025). Revenue: ₹5.06b (up 50% from 1Q 2025). Net income: ₹604.6m (up 332% from 1Q 2025). Profit margin: 12% (up from 4.1% in 1Q 2025). The increase in margin was driven by higher revenue. Revenue exceeded analyst estimates by 38%. Earnings per share (EPS) also surpassed analyst estimates. Revenue is forecast to grow 14% p.a. on average during the next 3 years, compared to a 16% growth forecast for the Life Sciences industry in India.
お知らせ • Jul 21Sai Life Sciences Limited to Report Q1, 2026 Results on Aug 07, 2025Sai Life Sciences Limited announced that they will report Q1, 2026 results on Aug 07, 2025
お知らせ • Jun 20TPG Reportedly to Sell 6% Stake in Sai Life Sciences at Estimated Price of $102 Million in Block DealTPG Inc. (NasdaqGS:TPG) is likely to sell 12.5 million shares representing 6% stake Sai Life Sciences Limited (NSEI:SAILIFE) at an estimated deal size of $102 million, according to a report. The base price of the deal is likely at INR 710 per share which is a discount of 2.5% over the current market price. There will be a 60-day lock-in period for the seller, a CNBC-TV18 report said, citing sources. TPG held over 51.5 million equity shares in the company as on March 31, 2025 through TPG Asia VII SF PTE Ltd, which accounts for a 24.73% stake in this smallcap company. The market capitalisation of the company is at INR 152,300 million.
Reported Earnings • May 14Full year 2025 earnings released: EPS: ₹8.83 (vs ₹4.57 in FY 2024)Full year 2025 results: EPS: ₹8.83 (up from ₹4.57 in FY 2024). Revenue: ₹17.3b (up 18% from FY 2024). Net income: ₹1.70b (up 106% from FY 2024). Profit margin: 9.8% (up from 5.7% in FY 2024). The increase in margin was driven by higher revenue. Revenue is forecast to grow 15% p.a. on average during the next 3 years, compared to a 15% growth forecast for the Life Sciences industry in India.
Board Change • May 08Less than half of directors are independentFollowing the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 3 non-independent directors. Independent Director Ramesh Iyer was the last independent director to join the board, commencing their role in 2024. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.
お知らせ • Apr 23Sai Life Sciences Limited Announces Change of Designation of Sauri Gudlavalleti to Head of Special Projects from Chief Operating Officer, Effective April 23, 2025Sai Life Sciences Limited announced that Mr. Sauri Gudlavalleti, who held the position of Chief Operating Officer, will move into the new role of Head of Special Projects with effect from the close of business on 23 April, 2025. The change in role of Mr. Sauri Gudlavalleti is pursuant his request received in this regard due to his personal commitments. He Ceased to be a part of senior management with effect from 23rd April, 2025.
お知らせ • Mar 25Sai Life Sciences Limited Announces Cessation of Rajagopal Srirama Tatta as Independent DirectorSai Life Sciences Limited announced cessation of Mr. Rajagopal Srirama Tatta as Independent Director of the Company with effect from the closing of Business hours on 25 March 2025, consequent to the end of his term as an Independent Director.
Recent Insider Transactions • Feb 27Insider recently sold ₹51m worth of stockOn the 21st of February, Tuneer Ghosh sold around 71k shares on-market at roughly ₹713 per share. This transaction amounted to 12% of their direct individual holding at the time of the trade. In the last 3 months, there was an even bigger sale from another insider worth ₹109m. Insiders have been net sellers, collectively disposing of ₹830m more than they bought in the last 12 months.
Reported Earnings • Feb 07Third quarter 2025 earnings releasedThird quarter 2025 results: EPS: ₹2.89. Net income: ₹538.5m (up ₹538.5m from 3Q 2024). Revenue is forecast to grow 19% p.a. on average during the next 3 years, compared to a 16% growth forecast for the Life Sciences industry in India.
お知らせ • Jan 25Sai Life Sciences Limited to Report Q3, 2025 Results on Feb 06, 2025Sai Life Sciences Limited announced that they will report Q3, 2025 results on Feb 06, 2025